Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy

Summary 18‐Fluorodeoxyglucose positron emission tomography (FDG‐PET) scans were performed on 27 patients with unresectable stage IIIC or IV melanoma after prolonged treatment with anti‐PD‐1 antibodies to examine the hypothesis that patients with prolonged response to treatment may have metabolically...

Full description

Saved in:
Bibliographic Details
Published in:Pigment cell and melanoma research 2016-09, Vol.29 (5), p.572-577
Main Authors: Kong, Benjamin Y., Menzies, Alexander M., Saunders, Catherine A. B., Liniker, Elizabeth, Ramanujam, Sangeetha, Guminski, Alex, Kefford, Richard F., Long, Georgina V., Carlino, Matteo S.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
anti-PD-1
Antineoplastic Agents - therapeutic use
FDG-PET
Female
Fluorodeoxyglucose F18 - metabolism
Humans
Lesions
Liver Neoplasms - diagnostic imaging
Liver Neoplasms - drug therapy
Liver Neoplasms - metabolism
Liver Neoplasms - secondary
Male
Melanoma
Melanoma - diagnostic imaging
Melanoma - drug therapy
Melanoma - metabolism
Melanoma - pathology
Middle Aged
Neoplasm Staging
nivolumab
pembrolizumab
Positron-Emission Tomography - methods
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Radiopharmaceuticals - metabolism
Survival Rate
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary 18‐Fluorodeoxyglucose positron emission tomography (FDG‐PET) scans were performed on 27 patients with unresectable stage IIIC or IV melanoma after prolonged treatment with anti‐PD‐1 antibodies to examine the hypothesis that patients with prolonged response to treatment may have metabolically inactive lesions by FDG‐PET. Scans were performed at a median of 15.2 months (range 12–29 months) after starting treatment. Overall, 15 of 27 (56%) patients had a positive FDG‐PET scan. Eight patients with positive scans underwent biopsy; 5 of 8 (62%) were melanoma and 3 of 8 (38%) were immune cell infiltrates. Of the 12 patients with negative FDG‐PET scans, six had residual computerized tomography‐visible lesions, five have ceased treatment, and none have recurred with follow‐up of 6–10 months. Patients with residual metastases after a prolonged period without progression on anti‐PD‐1 therapy may have metabolically inactive lesions. Isolated metabolically active lesions in clinically well patients may reveal immune cell infiltrates rather than melanoma.
ISSN:1755-1471
1755-148X
DOI:10.1111/pcmr.12503